• profile
  • History
  • Business Model
    • Portfolio Model
    • Licensing
  • Management Team
  • Board of Directors
  • Consultative Committee
  • Professional Affiliations

• products
  • Nimotuzumab
    • Science
    • Safety Profile
    • Clinical Trials
    • Consortium
    • Licensee Links
  • AeroLEF®
    • Science
    • Variable Dosing
    • Clinical Trials
  • CYT387
    • Science
    • Clinical Trials
  • CYT997
    • Science
    • Clinical Trials
  • Clinical Trials
  • Request Medical Info

• investors
  • Financial Reports
  • Regulatory Filings
  • Stock Information
  • Press Releases
  • Calendar of Events
  • Presentations
  • Corporate Governance
  • Investor Contacts
  • Email Sign-up
  • F.A.Q.

• patients
  • Nimotuzumab
    • Patients - Canada
    • Patients - USA
    • Patients - Worldwide
  • CYT387
  • CYT997
  • AeroLEF®

• physicians
  • Nimotuzumab
  • CYT387
  • CYT997
  • AeroLEF®

• contact
  • Investor Contacts
  • Licensing Contact
  • Clinical Contact

CYT387

CYT387 is a novel oral JAK1/JAK2 inhibitor initially targeting the treatment of a group of hematological disorders known as myeloproliferative neoplasms (MPNs), also known as myeloproliferative disorders. Additional potential treatment indications for CYT387 include other MPNs, cancer (solid and liquid tumors), graft-vs-host disease, and inflammatory conditions. The compound is currently being studied in a Phase I/II clinical trial at Mayo Clinic in patients with myelofibrosis.

CYT387 was developed by Australian biotech company Cytopia Research Pty Ltd, and is now part of the YM BioSciences development program.